कंपनी का अवलोकन
Electromed, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry where it designs, manufactures, markets, and sells airway clearance therapy products. The company's core business involves applying high frequency chest wall oscillation (HFCWO) therapy to provide pulmonary care for patients across the United States and internationally, with a primary product offering known as the SmartVest airway clearance system. As of the latest reporting period, the firm maintains a market capitalization of $203.59 million, generates annual revenue of $68.86 million, and employs a workforce of 177 individuals. These financial metrics suggest that Electromed holds a mid-cap position in the specialized medical device market, indicating a company that has achieved a level of market recognition sufficient to attract institutional interest while still operating with the agility of a smaller enterprise.
वित्तीय स्वास्थ्य
The company reported a revenue of $68.86 million over the trailing twelve months, resulting in a net income of $8.99 million and an EBITDA of $12.88 million. The difference between the revenue figure and the net income reveals a cost structure where approximately 8.69 million in operating expenses, taxes, and interest were deducted from total sales to arrive at the bottom line. Free cash flow stands at $7.08 million, which signifies that the company generates sufficient operational cash to cover capital expenditures and still retain a substantial amount of liquidity for strategic initiatives or debt servicing. Profitability is demonstrated through a gross margin of 78.2%, an operating margin of 19.2%, and a profit margin of 13.1%, indicating that the company retains a significant portion of revenue after the cost of goods sold and maintains efficient overhead management. The balance sheet presents a conservative profile with cash reserves of $13.79 million significantly outweighing total debt of $96,000, supported by a low debt-to-equity ratio of 0.21. Short-term liquidity is robust, evidenced by a current ratio of 4.86, which indicates that current assets are nearly five times greater than current liabilities, providing a wide safety margin against immediate obligations. Management effectiveness is further highlighted by a return on equity of 20.2% and a return on assets of 13.6%, showing that shareholders and asset holders are receiving strong returns relative to the capital employed.
मूल्यांकन आकलन
Valuation metrics indicate a trailing P/E ratio of 23.70 and a forward P/E of 40.02, suggesting that the market prices in significantly higher earnings growth expectations for the coming year compared to historical performance. The price-to-book ratio of 4.45 implies that the stock trades at a substantial premium over its book value, reflecting investor confidence in the company's intangible assets, brand value, and future growth prospects beyond tangible assets. Alternative valuation measures include a price-to-sales ratio of 2.96 and an EV/EBITDA of 14.62, which provide context for assessing the stock's value relative to its revenue generation and earnings power independent of capital structure changes. Price action has ranged between a 52-week high of $30.73 and a 52-week low of $17.73, illustrating the volatility and trading range within which the stock has moved during the past year. The beta value of 0.32 indicates that the stock exhibits low price volatility relative to the broader market, moving much less than the overall index during periods of market fluctuation.
Growth & Income
Electromed, Inc. demonstrates a revenue growth rate of 16.3% year-over-year paired with an earnings growth rate of 45.5% year-over-year, indicating that earnings are expanding at a rate nearly three times faster than top-line revenue growth. This divergence implies improved operational efficiency, favorable cost dynamics, or potentially one-time gains contributing to the accelerated profit expansion. The company does not currently pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all net income is retained within the business rather than distributed to shareholders. Consequently, the company reinvests its earnings into research, development, manufacturing capacity, or market expansion to fuel organic growth rather than providing income to investors. The overall growth and income profile is characterized by strong profitability acceleration and a capital allocation strategy focused on reinvestment rather than income distribution.